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The nationwide surveillance on antimicrobial susceptibility of bacterial respiratory pathogens from pa-
tients in Japan, was conducted by Japanese Society of Chemotherapy, Japanese Association for Infectious
Diseases and Japanese Society for Clinical Microbiology in 2010.
The isolates were collected from clinical specimens obtained from well-diagnosed adult patients
with respiratory tract infections during the period from January and April 2010 by three societies.
Antimicrobial susceptibility testing was conducted at the central reference laboratory according to the
method recommended by Clinical and Laboratory Standard Institutes using maximum 45 antibacterial
agents.
Susceptibility testing was evaluable with 954 strains (206 Staphylococcus aureus, 189 Streptococcus
pneumoniae, 4 Streptococcus pyogenes, 182 Haemophilus inﬂuenzae, 74 Moraxella catarrhalis, 139 Klebsiella
pneumoniae and 160 Pseudomonas aeruginosa). Ratio of methicillin-resistant S. aureus was as high as
50.5%, and those of penicillin-intermediate and -resistant S. pneumoniaewere 1.1% and 0.0%, respectively.
Among H. inﬂuenzae, 17.6% of them were found to be b-lactamase-non-producing ampicillin (ABPC)-
intermediately resistant, 33.5% to be b-lactamase-non-producing ABPC-resistant and 11.0% to be b-lac-
tamase-producing ABPC-resistant strains. Extended spectrum b-lactamase-producing K. pneumoniae and
multi-drug resistant P. aeruginosa with metallo b-lactamase were 2.9% and 0.6%, respectively.
Continuous national surveillance of antimicrobial susceptibility of respiratory pathogens is crucial in
order to monitor changing patterns of susceptibility and to be able to update treatment recommenda-
tions on a regular basis.
© 2015, Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases.
Published by Elsevier Ltd. All rights reserved.1. Introduction
In order to investigate comprehensively the antimicrobial sus-
ceptibility and resistance of bacterial respiratory pathogens, Japa-
nese Society of Chemotherapy (JSC) established a nationwide
surveillance network in 2006. The ﬁrst survey was conducted in
2006 and we reported the trend of antimicrobial susceptibilities of
bacterial species from patients with respiratory tract infections
(RTI) [1]. Second and third surveys were continuously conducted in
2007 and in 2008, respectively. After third-year study, this survey
was decided to be continued in association with JSC, the Japanese
Association for Infectious Diseases and the Japanese Society for
Clinical Microbiology. In 2009, the fourth year nationwide surveil-
lance was conducted as the ﬁrst survey conducted by three soci-
eties [2]. Here we report the study of ﬁfth year nationwide
surveillance which was the second survey conducted by three so-
cieties. These results obtained from this surveillance will be used asa set of controls for those conducted in future by three societies and
by other organizations as well.
2. Materials and methods
2.1. Strains and quality control
The bacteria from the patients with RTI were isolated from
sputum, specimens collected by trans-tracheal aspiration, or
bronchoscopy between April and September in 2010. The subjects
in the study were Staphylococcus aureus, Streptococcus pneumoniae,
Streptococcus pyogenes, Haemophilus inﬂuenzae, Moraxella catar-
rhalis, Klebsiella pneumoniae and Pseudomonas aeruginosa. Micro-
biological laboratory test for respiratory pathogens were conducted
by standard methods including Gram staining and quantitative
culture of various respiratory samples at 34 medical institutions, as
listed in Table 1. The isolated bacteria were identiﬁed as species
Table 1
List of participating institution contributing to our surveillance.
Asahikawa Medical University, Hokkaido, Japan
Iwate Prefectural Central Hospital, Iwate, Japan
Saiseikai Yamagata Saisei Hospital, Yamagata, Japan
Japanese Red Cross Sendai Hospital, Miyagi, Japan
Saka General Hospital, Miyagi, Japan
Teikyo University School of Medicine, Tokyo, Japan
National Center for Global Health and Medicine, Tokyo, Japan
National Hospital Organization Tokyo Medical Center, Tokyo, Japan
Kyorin University Hospital, Tokyo, Japan
Showa University, School of Medicine, Tokyo, Japan
National Defense Medical College, Saitama, Japan
Yokohama City University Hospital, Kanagawa, Japan
Toyama Prefectural Central Hospital, Toyama, Japan
Niigata City General Hospital, Niigata, Japan
Shinrakuen Hospital, Niigata, Japan
Kasugai Municipal Hospital, Aichi, Japan
Aichi Medical University Hospital, Aichi, Japan
Kinki University, Faculty of Medicine, Osaka, Japan
Osaka City General Hospital, Osaka, Japan
Center for Infectious Diseases, Nara Medical University, Nara, Japan
Kobe Red Cross Hospital, Hyogo, Japan
Osaka University Hospital, Osaka, Japan
Kawasaki Medical School, Okayama, Japan
Okayama University Hospital, Okayama, Japan
Hiroshima Prefectural Hospital, Hiroshima, Japan
Matsue Red Cross Hospital, Shimane, Japan
Kagawa University Hospital, Kagawa, Japan
Oita University Faculty of Medicine, Oita, Japan
Saga University, School of Medicine, Saga, Japan
Saiseikai Kumamoto Hospital, Kumamoto, Japan
Nagasaki University School of Medicine, Nagasaki, Japan
St. Mary's Hospital, Fukuoka, Japan
Faculty of Medicine, Fukuoka University, Fukuoka, Japan
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the causative bacteria judged by physicians were collected. When
several strains were detected from the same patient, arbitrary 1
strain was selected. The isolates were suspended in Micro-bank
tube (Asuka Junyaku Co.Ltd. Tokyo) and transferred to the central
laboratory, the Research Center for Anti-infective Drugs of the
Kitasato Institute. The electronic uniform data sheets of each pa-
tient fromwhom these strains isolated were also completed at each
institution and sent to the Center so that microbiological data ob-
tained were able to be stratiﬁed under the settings and proﬁles of
patients and under the diagnoses.
A total of 1001 strains were received at the center and kept
at 80 C until the antimicrobial susceptibility testing conducted.
Re-identiﬁcation and cultivation of them gave evaluable 954 strains
consisted of 206 S. aureus, 189 S. pneumoniae, 4 S. pyogenes, 182
H. inﬂuenzae, 74 M. catarrhalis, 139 K. pneumoniae and 160
P. aeruginosa.
Accuracy of determination for minimum inhibitory concentra-
tion (MIC) of antibacterial agents was controlled according to the
recommendations of Clinical and Laboratory Standards Institute
(CLSI) using the following control strains respectively: S. aureus
ATCC29213 and Escherichia coli ATCC35218 for clinical isolates of
S. aureus and M. catarrhalis; S. pneumoniae ATCC49619 for
S. pneumoniae; H. inﬂuenzae ATCC49247 for H. inﬂuenzae; E. coli
ATCC25922 for K. pneumoniae and P. aeruginosa; and P. aeruginosa
ATCC27853 for P. aeruginosa. E. coli ATCC35218 was used as a
control strain in case of MIC determination for b-lactam antibiotics
combined with b -lactamase inhibitors.2.2. Antibacterial agents
The susceptibilities of the bacterial strains were tested for the
following 45 antimicrobial agents: four penicillins such asbenzylpenicillin (PCG; Meiji Seika Kaisha Ltd.), oxacillin (MPIPC;
Meiji), ampicillin (ABPC; Meiji) and piperacillin (PIPC; Toyama
Chemical Co., Ltd.); three penicillins in combination with b-lac-
tamase inhibitors such as clavulanic acid-amoxicillin (CVA/AMPC;
Glaxo SmithKline K.K.), sulbactam-ABPC (SBT/ABPC; Pﬁzer Japan
Inc.) and tazobactam-PIPC (TAZ/PIPC; Toyama); four oral cephems
such as cefaclor (CCL; Shionogi & Co., Ltd.), cefdinir (CFDN;
Astellas Pharma Inc.), cefcapene (CFPN; Shionogi), and cefditoren
(CDTR; Meiji); eight parenteral cephems such as cefazolin (CEZ;
Astellas), cefoxitin (CFX; Banyu Pharmaceutical Co., Ltd.), cefme-
tazole (CMZ; Daiichi-Sankyo Co., Ltd.), cefotiam (CTM; Takeda
Pharmaceutical Co., Ltd.), ceftazidime (CAZ; Glaxo SmithKline),
ceftriaxone (CTRX; Chugai Pharmaceutical Co., Ltd.), cefepime
(CFPM; Meiji) and cefozopran (CZOP; Takeda); a monobactam
aztreonam (AZT; Eisai Co., Ltd.); ﬁve carbapenems such as imi-
penem (IPM; Banyu), panipenem (PAPM; Daiichi-Sankyo), mer-
openem (MEPM; Dainippon Sumitomo Pharma Co., Ltd.),
biapenem (BIPM; Meiji) and doripenem (DRPM; Shionogi); one
penem such as faropenem (FRPM; Astellas); four aminoglycosides
such as gentamicin (GM; Shionogi), tobramycin (TOB; J-dolph),
amikacin (AMK; Banyu) and arbekacin (ABK; Meiji); three mac-
rolides such as erythromycin (EM; Dainippon Sumitomo), clari-
thromycin (CAM; Toyama) and azithromycin (AZM; Pﬁzer); a
lincosamide clindamycin (CLDM; Dainippon Sumitomo); a tetra-
cycline minocycline (MINO; Wyeth K.K./Takeda); two glycopep-
tides such as vancomycin (VCM; Shionogi) and teicoplanin (TEIC;
Astellas); seven ﬂuoroquinolones such as ciproﬂoxacin (CPFX;
BayerYakuhin Ltd.), levoﬂoxacin (LVFX; Daiichi-Sankyo), tosu-
ﬂoxacin (TFLX; Toyama), moxiﬂoxacin (MFLX; Shionogi), pazu-
ﬂoxacin (PZFX; Toyama), garenoxacin (GRNX; Astellas), and
sitaﬂoxacin (STFX; Daiichi Sankyo) and an oxazolidinone line-
zolide (LZD; Pﬁzer). These antimicrobial agents were serially
diluted and placed under freeze-dried state in respective wells of
microplates. The stability of the antimicrobial agent-containing
microplates was guaranteed by the manufacturer (Eiken
Kagaku) for 9 months.
2.3. Susceptibility testing and MIC determination
Susceptibility testing was performed according to CLSI stan-
dards M7-A8 for micro-broth dilutionmethod [3,4]. In brief, cation-
adjustedMueller-Hinton broth (25mg/L Caþþ and 12.5 mg/L Mgþþ;
CAeMH broth) was used to measure MIC against S. aureus, M.
catarrhalis, K. pneumoniae and P. aeruginosa. For the determination
of the MIC of oxacillin, NaCl was added at 2% to CAeMH broth. For
measuring the MICs against S. pneumoniae and H. inﬂuenzae, 15 mg/
mL nicotinamide, 5 mg/mL yeast-extract and horse blood at 5%
were added to CAeMH broth.
A 0.005 mL portion of test organism solution, grown to turbidity
of McFarland Number 0.5 and diluted tenfold with saline, was
inoculated to CAeMHbroth tomake a ﬁnal volume of 0.1± 0.02mL.
This was poured into a well on a microplate (Eiken Kagaku Co., Ltd.,
Tokyo, Japan) serially diluted freeze-dried test agent was placed,
and the MIC was determined with the MIC2000 system (Eiken
Kagaku Co., Ltd., Tokyo). Tested ranges were 0.06e128 mg/ml for
CFDN, CDTR, CAM, and AZM, 0.06e32 mg/ml for TFLX, and
0.06e256 mg/ml for the other antimicrobials.
2.4. Detection of b-lactamases
To detect b-lactamases in H. inﬂuenzae, tests with Nitoroceﬁn
desks (Kanto Chemical Co, Inc., Tokyo)were conducted according to
the reference manual supplied by the manufacturer.
A recently established rapid detection method, the CicaeBeta
Test 1® (Kanto Chemical Co, Inc., Tokyo) being designed to detect
Table 2
Antibacterial susceptibility of Staphylococcus aureus.
Antibacterial agent All strains, n ¼ 206
MIC (mg/ml) Susceptibility (%)
50% 90% Range S I R
PCG 8 32 0.06 to 64 25.7 e 74.3
MPIPC 8 256 0.125 to 256 49.5 e 50.5
ABPC 8 32 0.06 to 64 26.2 73.8
SBT/ABPC 4 32 0.06 to 64 59.7 27.2 13.1
CVA/AMPC 2 32 0.125 to64 53.4 e 46.6
PIPC 16 128 0.5 to 256 e e e
TAZ/PIPC 4 128 0.25 to 256 53.4 e 46.6
CCL 8 128 0.5 to 256 50.0 2.9 47.1
CFDN 1 128 0.125 to 128 50.5 2.9 46.6
CFPN 4 256 0.25 to 256 e e e
CDTR 4 128 0.25 to 128 e e e
CEZ 2 256 0.125 to256 54.4 0.5 45.1
CFX 8 256 2 to 256 49.0 e 51.0
CMZ 2 64 0.5 to 128 65.5 18.5 16.0
CTM 2 256 0.25 to 256 e e e
CAZ 16 128 4 to 128 48.5 3.9 47.6
CTRX 8 256 1 to 256 50.0 4.9 45.1
CFPM 4 256 1 to 256 53.9 1.0 45.1
CZOP 1 64 0.5 to 128 e e e
IPM 0.06 32 0.06 to 128 61.7 5.8 32.5
PAPM 0.125 16 0.06 to 64 e e e
MEPM 0.25 32 0.06 to 64 59.2 8.8 32.0
BIPM 0.25 32 0.06 to 128 e e e
DRPM 0.125 16 0.06 to 32 e e e
FRPM 0.25 256 0.06 to 256 e e e
GM 0.25 64 0.06 to 256 66.5 2.9 30.6
TOB 1 256 0.06 to 256 50.5 3.4 46.1
AMK 4 16 0.5 to 128 95.6 2.5 1.9
ABK 0.5 1 0.125 to 2 e e e
EM 256 256 0.125 to 256 36.4 1.0 62.6
CAM 128 128 0.125 to 128 36.9 1.0 62.1
AZM 128 128 0.25 to 128 36.4 0.5 63.1
CPFX 2 128 0.06 to 256 49.5 0.5 50.0
LVFX 1 256 0.06 to 256 50.0 0 50.0
TFLX 0.25 32 0.06 to 32 e e e
MFLX 0.125 32 0.06 to 64 50.0 7.8 42.2
PZFX 0.5 256 0.125 to 256 e e e
GRNX 0.125 32 0.06 to 64 e e e
STFX 0.125 8 0.06 to 16 e e e
MINO 0.125 16 0.06 to 32 69.9 6.8 23.3
CLDM 0.25 256 0.06 to 256 54.4 0 45.6
VCM 1 1 0.25 to 2 100 0 0
TEIC 1 2 0.06 to 8 100 0 0
LZD 2 2 1 to 2 100 e 0
The susceptibility of 44 antimicrobial agents against 206 strains of S.aureus was determined. PCG benzylpenicillin, MPIPC oxacillin, ABPC ampicillin, PIPC piperacillin, CVA/
AMPC clavulanic acid - amoxicillin, SBT/ABPC sulbactam - ABPC, TAZ/PIPC tazobactam e PIPC (tazobactam: PIPC ¼ 1: 8), CCL cefaclor, CFDN cefdinir, CFPN cefcapene, CDTR
cefditoren, CEZ cefazolin, CFX cefoxitin, CMZ cefmetazole, CTM cefotiam, CAZ ceftazidime, CTRX ceftriaxone, CFPM cefepime, CZOP cefozopran, AZT aztreonam, IPM imipenem,
PAPM panipenem, MEPM meropenem, BIPM biapenem, DRPM doripenem, FRPM faropenem, GM gentamicin, TOB tobramycin, AMK amikacin, ABK arbekacin, EM erythro-
mycin, CAM clarithromycin, AZM azithromycin, CLDM clindamycin, MINO minocycline, VCM vancomycin, TEIC teicoplanin, CPFX ciproﬂoxacin, LVFX levoﬂoxacin, TFLX
tosuﬂoxacin, MFLX moxiﬂoxacin, PZFX pazuﬂoxacin, GRNX garenoxacin, STFX sitaﬂoxacin, LZD linezolid.
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(MBL) directly in colonies of Gram-negative rods [5], was employed
to identify K. pneumoniae and P. aeruginosa strains which produce
such b-lactamases.3. Results
3.1. Staphylococcus aureus
The in vitro antimicrobial susceptibilities, as MIC50 ⁄ MIC90
values, and the range of MICs for S. aureus isolates are shown in
Table 2. Among the total 206 strains of S. aureus, 104 strains (50.5%)
were found to be methicillin-resistant S. aureus (MRSA; MIC of
MPIPC  4 mg/mL) [Table 3].3.2. Susceptibility of methicillin-susceptible S. aureus (MSSA)
The MIC90s of penicillins against 102 MSSA strains were
4.0e8.0 mg/mL; however, the MIC90 of penicillins in combinations
with b-lactamase inhibitors (CVA/AMPC, SBT/ABPC and TAZ/PIPC)
decreased to 1.0e4.0 mg/mL. The MIC90s of CCL, CAZ, CTRX, CFPM
and CFX ranged from 2.0 to 8.0 mg/mL and those of the other seven
cephems from 0.25 to 1.0 mg/mL. Carbapenems showed the stron-
gest activity, with MIC90s of 0.125 mg/mL. As for aminoglycosides,
GM, TOB, AMK and ABK showedMIC90 of 8.0, 8.0, 4.0 and 0.5 mg/mL,
respectively. Among the macrolide-lincosamide antibiotics, CLDM
showed relatively strong activity with MIC90 of 0.25 mg/mL, but the
rest of macrolides showed weak activity with MIC90s of 128 mg/
mL. Relatively strong activities of MINO, VCM, TEIC and LZD were
shown, with MIC90s of 0.125e2.0 mg/mL. MIC90s of the seven
Table 3
Antibacterial susceptibility of Staphylococcus aureus (MRSA and MSSA).
Antibacterial agent MRSA, n ¼ 104 MSSA, n ¼ 102
MIC (mg/ml) Susceptibility (%) MIC (mg/ml) Susceptibility (%)
50% 90% Range S I R 50% 90% Range S I R
PCG 16 32 4 to 64 0 e 100 0.125 8 0.06 to 32 52.0 e 48.0
MPIPC 128 256 8 to 256 0 e 100 0.25 0.5 0.125 to 2 100 e 0
ABPC 32 32 8 to 64 0 e 100 0.25 4 0.06 to 16 52.9 e 47.1
SBT/ABPC 16 32 2 to 64 20.2 53.8 26.0 0.25 1 0.06 to 4 100 0 0
CVA/AMPC 16 32 2 to 64 7.7 e 92.3 0.25 1 0.125 to 2 100 e 0
PIPC 128 256 8 to 256 e e e 1 8 0.5 to 32 e e e
TAZ/PIPC 64 256 4 to 256 7.7 e 92.3 0.5 1 0.25 to 2 100 e 0
CCL 128 256 8 to 256 1.0 5.7 93.3 1 2 0.5 to 8 100 0 0
CFDN 128 128 1 to 128 1.9 5.8 92.2 0.25 0.5 0.125 to 0.5 100 0 0
CFPN 256 256 4 to 256 e e e 1 1 0.25 to 2 e e e
CDTR 64 128 4 to 128 e e e 0.5 1 0.25 to 2 e e e
CEZ 256 256 2 to 256 9.6 1.0 89.4 0.25 0.5 0.125 to 1 100 0 0
CFX 128 256 8 to 256 0 e 100 2 4 2 to 8 99.0 e 1.0
CMZ 32 128 2 to 128 31.7 36.6 31.7 1 1 0.5 to 1 100 0 0
CTM 128 256 2 to 256 e e e 0.5 1 0.25 to 1 e e e
CAZ 128 128 8 to 128 1.0 4.8 94.2 8 8 4 to 16 97.1 2.9 0
CTRX 256 256 8 to 256 1.0 9.6 89.4 4 4 1 to 8 100 0 0
CFPM 128 256 4 to 256 8.7 1.9 89.4 2 2 1 to 4 100 0 0
CZOP 32 64 1 to 128 e e e 1 1 0.5 to 1 e e e
IPM 16 64 0.06 to 128 24.0 11.6 64.4 0.06 0.06 0.06 to 0.125 100 0 0
PAPM 16 32 0.06 to 64 e e e 0.06 0.06 0.06 to 0.125 e e e
MEPM 16 32 0.25 to 64 19.2 17.3 63.5 0.06 0.125 0.06 to 0.125 100 0 0
BIPM 16 64 0.25 to 128 e e e 0.06 0.06 0.06 to 0.125 e e e
DRPM 8 16 0.125 to 32 e e e 0.06 0.06 0.06 to 0.125 e e e
FRPM 256 256 0.25 to 256 e e e 0.06 0.125 0.06 to 0.125 e e e
GM 16 64 0.06 to 256 44.2 2.9 52.9 0.25 8 0.125 to 256 89.2 3.0 7.8
TOB 128 256 0.25 to 256 12.5 3.8 83.7 0.5 8 0.06 to 64 89.2 3.0 7.8
AMK 8 16 0.5 to 128 91.3 4.9 3.8 2 4 0.5 to 8 100 0 0
ABK 0.5 1 0.125 to 2 e e e 0.5 0.5 0.125 to 2 e e e
EM 256 256 0.25 to 256 1.0 0 99.0 0.25 256 0.125 to 256 72.5 2.0 25.5
CAM 128 128 0.25 to 128 1.0 0 99.0 0.25 128 0.125 to 128 73.5 2.0 24.5
AZM 128 128 1 to 128 1.0 0 99.0 1 128 0.25 to 128 72.5 1.0 26.5
CPFX 128 256 0.125 to 256 6.7 0 93.3 0.5 1 0.06 to 256 93.1 1.0 5.9
LVFX 32 256 0.125 to 256 6.7 0 93.3 0.25 0.5 0.06 to 256 94.1 0 5.9
TFLX 32 32 0.06 to 32 e e e 0.06 0.125 0.06 to 32 e e e
MFLX 8 32 0.06 to 64 6.7 13.5 79.8 0.06 0.125 0.06 to 64 94.1 2.0 3.9
PZFX 16 256 0.125 to 256 e e e 0.25 0.25 0.125 to 256 e e e
GRNX 4 32 0.06 to 64 e e e 0.06 0.06 0.06 to 32 e e e
STFX 2 8 0.06 to 16 e e e 0.06 0.06 0.06 to 16 e e e
MINO 8 16 0.06 to 32 42.3 11.5 46.2 0.125 0.125 0.06 to 8 98.0 2.0 0
CLDM 256 256 0.125 to 256 12.5 0 87.5 0.125 0.25 0.06 to 256 97.1 0 2.9
VCM 1 1 0.25 to 2 100 0 0 1 1 0.25 to 2 100 0 0
TEIC 1 2 0.25 to 8 100 0 0 0.5 1 0.06 to 4 100 0 0
LZD 2 2 1 to 2 100 e 0 2 2 1 to 2 100 e 0
The susceptibility of 44 antimicrobial agents against 104 strains of MRSA and 102 strains of MSSA was determined. Ratio of MRSA was 50.5%.
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and STFX showed the strongest activities among the
ﬂuoroquinolones.
3.3. Susceptibility of MRSA
Only four agents, ABK, VCM, TEIC and LZD, showed strong ac-
tivity against MRSAwith MIC90 of 2.0 mg/mL. MINO showed weak
activity with MIC90s of 16 mg/mL. Other agents showed almost no
activity, with MIC90s of 32 mg/mL.
3.4. Streptococcus pneumoniae
The susceptibilities of the 189 strains of S. pneumoniae to PCG
revealed that 187 strains (98.9%), 2 strains (1.1%), and 0 strains
(0.0%) were identiﬁed as penicillin-susceptible (PSSP), penicillin-
intermediate (PISP), and penicillin-resistant strains (PRSP),
respectively, with the breakpoint for PCG deﬁned by the CLSI
standards [Table 4].
Among the b-lactams, CCL, CAZ and CMZ showed high MIC90s
(64, 8 and 16 mg/mL, respectively) while many of the other b-lactams, except for the carbapenems, showed potent activities,
with MIC90s of 1.0e4.0 mg/mL. All ﬁve carbapenems showed strong
activities (MIC90: 0.25 mg/mL) against all S. pneumoniae strains,
regardless of their different susceptibilities to PCG. Fluo-
roquinolones also showed potent activities against the strains with
MIC90s of 0.06e2 mg/mL. STFX was the strongest ﬂuoroquinolone
and the MIC against all strains was 0.5 mg/mL. The glycopeptides
(VCM and TEIC) showed strong activities (MIC90: 0.5 mg/mL).
Aminoglycosides were substantially less active, with MIC90s of
8.0e64.0 mg/mL. High frequencies of resistance against the mac-
rolide antibiotics, EM, CAM, and AZM, were shown, with MIC90s of
128 mg/mL.
3.5. Streptococcus pyogenes
The susceptibilities of the 4 S. pyogenes strains are summarized
in Table 5. All b-lactams showed strong activities (MIC90: 0.5 mg/
mL). Aminoglycosides and macrolides were less active, with MIC90s
of 8.0e256 mg/mL. Among ﬂuoroquinolones, MFLX, GRNX and
STFX showed potent activities (MIC90: 0.25 mg/mL), while the
MIC90 of PZFX was 4.0 mg/mL.
Table 4
Antibacterial susceptibility of Streptococcus pneumoniae.
Antibacterial agent All strains, n ¼ 189 PSSP, n ¼ 187 PISP, n ¼ 2
MIC(mg/ml) Susceptibility (%) MIC(mg/ml) Susceptibility (%) MIC(mg/ml)
50% 90% Range S I R 50% 90% Range S I R 50% 90%
PCG 0.25 2 0.06 to 4 42.9 41.8 15.3 0.25 2 0.06 to 2 100 0 0 4 4
ABPC 0.25 2 0.06 to 8 e e e 0.25 2 0.06 to 4 e e e 8 8
SBT/ABPC 0.25 2 0.06 to 8 e e e 0.25 2 0.06 to 4 e e e 8 8
CVA/AMPC 0.125 1 0.06 to 4 99.5 0.5 0 0.125 1 0.06 to 2 100 0 0 1 4
PIPC 0.25 2 0.06 to 8 e e e 0.25 2 0.06 to 4 e e e 4 8
TAZ/PIPC 0.25 2 0.06 to 4 e e e 0.25 2 0.06 to 4 e e e 4 4
CCL 4 64 0.25 to 128 41.8 6.3 51.9 4 64 0.25 to 128 42.2 6.5 51.3 128 128
CFDN 0.5 4 0.06 to 32 50.8 10.6 38.6 0.5 4 0.06 to 32 51.3 10.7 38.0 8 16
CFPN 0.25 1 0.06 to 16 e e e 0.25 1 0.06 to 16 e e e 1 4
CDTR 0.125 0.5 0.06 to 4 e e e 0.125 0.5 0.06 to 4 e e e 1 2
CEZ 0.5 2 0.06 to 32 e e e 0.5 2 0.06 to 32 e e e 4 32
CMZ 1 16 0.06 to 64 e e e 1 16 0.06 to 32 e e e 32 64
CTM 0.5 4 0.06 to 32 e e e 0.5 4 0.06 to 16 e e e 4 32
CAZ 4 8 0.06 to 64 e e e 4 8 0.06 to 64 e e e 16 16
CTRX 0.5 1 0.06 to 4 96.8 1.1 2.1 0.5 1 0.06 to 4 97.9 0.5 1.6 2 4
CFPM 0.5 1 0.06 to 8 95.8 3.2 1.1 0.5 1 0.06 to 8 96.3 2.6 1.1 1 2
CZOP 0.5 1 0.06 to 4 e e e 0.5 1 0.06 to 4 e e e 2 4
IPM 0.06 0.25 0.06 to 1 77.2 21.2 1.6 0.06 0.25 0.06 to 1 78.1 20.8 1.1 0.5 1
PAPM 0.06 0.125 0.06 to 0.25 e e e 0.06 0.125 0.06 to 0.25 e e e 0.125 0.25
MEPM 0.06 0.25 0.06 to 1 92.6 6.3 1.1 0.06 0.25 0.06 to 1 93.6 5.9 0.5 0.5 1
BIPM 0.06 0.25 0.06 to 1 e e e 0.06 0.25 0.06 to 0.5 e e e 0.5 1
DRPM 0.06 0.25 0.06 to 1 e e e 0.06 0.25 0.06 to 0.5 e e e 0.5 1
FRPM 0.06 0.25 0.06 to 2 e e e 0.06 0.25 0.06 to 1 e e e 0.5 2
GM 8 8 1 to 16 e e e 8 8 1 to 16 e e e 4 8
TOB 16 32 4 to 32 e e e 16 32 4 to 32 e e e 8 16
AMK 64 64 8 to 128 e e e 64 64 8 to 128 e e e 32 64
ABK 16 32 4 to 64 e e e 16 32 4 to 64 e e e 16 32
EM 256 256 0.06 to 256 11.1 0 88.9 256 256 0.06 to 256 11.2 0 88.8 256 256
CAM 128 128 0.06 to 128 11.6 0.6 87.8 128 128 0.06 to 128 11.8 0.5 87.7 128 128
AZM 128 128 0.06 to 128 11.1 1.1 87.8 128 128 0.06 to 128 11.2 1.1 87.7 128 128
CPFX 1 2 0.06 to 64 e e e 1 2 0.06 to 64 e e e 1 64
LVFX 1 2 0.5 to 64 97.9 0.5 1.6 1 2 0.5 to 64 98.4 0.5 1.1 1 16
TFLX 0.25 0.25 0.06 to 32 e e e 0.25 0.25 0.06 to 16 e e e 0.25 32
MFLX 0.25 0.25 0.125 to 4 98.4 0.5 1.1 0.25 0.25 0.125 to 4 98.9 0.6 0.5 0.25 4
PZFX 2 4 1 to 64 e e e 2 4 1 to 64 e e e 2 32
GRNX 0.06 0.06 0.06 to 1 e e e 0.06 0.06 0.06 to 0.5 e e e 0.06 1
STFX 0.06 0.06 0.06 to 0.5 e e e 0.06 0.06 0.06 to 0.5 e e e 0.06 0.5
MINO 16 32 0.06 to 64 e e e 16 32 0.06 to 64 e e e 8 8
CLDM 128 256 0.06 to 256 40.2 0 59.8 128 256 0.06 to 256 40.6 0 59.4 128 128
VCM 0.25 0.5 0.06 to 0.5 100 e 0 0.25 0.5 0.06 to 0.5 100 e 0 0.25 0.5
TEIC 0.125 0.125 0.06 to 0.25 e e e 0.125 0.125 0.06 to 0.25 e e e 0.06 0.125
LZD 1 1 0.06 to 2 100 e 0 1 1 0.06 to 2 100 e 0 0.5 0.5
The susceptibility of 42 antimicrobial agents against 189 strains of S.pneumoniae was determined. Ratio of peniciliin-susceptible, penicillin-intermediate and penicillin
resistant S. pneumoniae (PSSP, PISP and PRSP) was 98.9%, 1.1% and 0%, respectively.
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The susceptibilities of the 182 H. inﬂuenzae strains are summa-
rized in Table 6 and Table 7. According to the CLSI breakpoint for
ABPC, 69 (37.9%) were found to be ABPC-susceptible, 32 (17.6%) to
be ABPC-intermediate and 61 (33.5%) to be ABPC-resistant. With
the use of the Nitrocephin disks, all ABPC-intermediate and ABPC-
resistant strains were found to be b-lactamase-non-producing, and
they were deﬁned as BLNAI and BLNAR, respectively. The other 20
(11.0%) ABPC-resistant strains were found to be b-lactamase-pro-
ducing strains, designated as BLPAR. The MIC50 and MIC90 values of
PCG and ABPC for BLPAR isolates were at least threefold higher than
those for BLNAR isolates. However, there were no differences in the
MIC50 and MIC90 values of SBT/ABPC and CVA/AMPC among BLNAR
isolates and BLPAR isolates. Regardless of susceptibility to ABPC, all
of the H. inﬂuenzae strains were extremely susceptible to all seven
ﬂuoroquinolones (MIC50s: 0.06 mg/mL). STFX showed a potent
activity and the maximum MIC value was 0.25 mg/mL, whereas
those of the other ﬂuoroquinolones were 4.0-32 mg/mL. BLPARstrains showed high levels of resistance against PIPC, with MIC90
values of 256 mg/mL, whereas TAZ/PIPC showed strong activities,
with MIC90s of 1.0 mg/mL. Among the cephems, CDTR, CAZ and
CTRX showed the most potent activities, with MIC90s of 0.06 mg/
mL. Of the ﬁve carbapenem agents, MEPM showed the most potent
activity against all types of H. inﬂuenzae strains. Among macrolide,
AZM showed the most potent activity, with MIC90s of 2.0 mg/mL.
3.7. Moraxella catarrhalis
The susceptibilities of 74 M. catarrhalis strains are shown in
Table 8. For the penicillins, b-lactamase inhibitors restored the ac-
tivities of penicillins; e.g., SBT decreased the MIC90 of ABPC from 16
to 0.25 mg/mL and TAZ decrease the MIC90 of PIPC from 8.0 to
0.125 mg/mL. Carbapenems showed strong activities, with MIC90s of
0.06 mg/mL. Fluoroquinolones also showed strong activities, with
MIC90s of 0.06 mg/mL (CPFX, TFLX, PZFX, GRNX and STFX). Several
cephems (CFDN, CFPN, CDTR, CAZ and CMZ), four aminoglycosides
(GM, TOB, AMK and ABK), and three macrolides (EM, CAM, and
Table 5
Antibacterial susceptibility of Streptococcus pyogenes.
Antibacterial agent All strains, n ¼ 4
MIC(mg/ml)
50% 90%
PCG 0.06 0.06
ABPC 0.06 0.06
SBT/ABPC 0.06 0.06
CVA/AMPC 0.06 0.06
PIPC 0.06 0.06
TAZ/PIPC 0.06 0.06
CCL 0.06 0.06
CFDN 0.06 0.06
CFPN 0.06 0.06
CDTR 0.06 0.06
CEZ 0.06 0.125
CMZ 0.25 0.5
CTM 0.06 0.06
CAZ 0.125 0.125
CTRX 0.06 0.06
CFPM 0.06 0.06
CZOP 0.06 0.06
IPM 0.06 0.06
PAPM 0.06 0.06
MEPM 0.06 0.06
BIPM 0.06 0.06
DRPM 0.06 0.06
FRPM 0.06 0.06
GM 4 8
TOB 8 16
AMK 32 64
ABK 8 16
EM 1 256
CAM 0.5 128
AZM 0.25 128
CPFX 0.5 2
LVFX 0.5 1
TFLX 0.125 0.5
MFLX 0.125 0.25
PZFX 1 4
GRNX 0.06 0.25
STFX 0.06 0.06
MINO 0.125 8
CLDM 0.06 128
VCM 0.25 0.5
TEIC 0.06 0.125
LZD 1 1
The susceptibility of 42 antimicrobial agents against 4 strains of S. pyogenes was
determined.
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0.125e1.0 mg/mL.3.8. Klebsiella pneumoniae
The susceptibilities of 139 K. pneumoniae strains are shown in
Table 9. Carbapenems showed strong activities, with MIC90s of
0.5 mg/mL; in particular, MEPM showed themost potent activities,
with MIC90s  0.06 mg/mL. Of the cephems and the monobactam,
CFPM showed the most potent activity, with MIC90s  0.06 mg/mL,
and CFDN, CTM, CAZ, CTRX, CZOP and AZT also showed strong ac-
tivities, with MIC90s of 0.125e0.25 mg/mL. All ﬂuoroquinolones we
tested and three aminoglycosides (GM, TOB and ABK) showed
potent activities, with MIC90s of 0.5e2.0 mg/mL b-lactamase in-
hibitors apparently restored the activities of penicillins; e.g., SBT
decreased the MIC90 of ABPC from 128 to 8 mg/mL and TAZ
decreased the MIC90 of PIPC from 16 to 8.0 mg/mL. Proportions of
susceptible/intermediate/resistant for CEZ, CAZ, CTRX and AZT
were 96.4/0.0/3.6, 98.6/0.7/0.7, 97.8/0.0/2.2 and 97.8/1.4/0.7,respectively. Four of 139 strains (2.9%) were found to be ESBL-
producing strains.3.9. Pseudomonas aeruginosa
A total 160 P. aeruginosa strains were tested for antimicrobial
susceptibility [Table 10]. Among the b-lactams, three carbapenems
(MEPM, BIPM and DRPM) showed potent activities, with MIC50s of
0.5 mg/mL; however, these agents showed relatively higher MIC90
levels, of 8.0e16 mg/mL. Among the ﬂuoroquinolones, STFX showed
themost potent activity, withMIC50s andMIC90s of 0.25 and 4.0 mg/
mL, respectively. Other ﬂuoroquinolones also showed strong ac-
tivities with MIC50s of 0.25e2.0 mg/mL, whereas MIC90 levels (8.0 to
32 mg/mL) suggested partial resistance. Both PIPC and TAZ/PIPC
showed potent activities, with MIC50s of 8.0 mg/mL, but higher
levels of MIC90s (128 mg/mL) of these agents were also observed.
The MIC50s of the four aminoglycosides (GM, TOB, AMK and ABK),
three cephems (CAZ, CFPM and CZOP), and the monobactam (AZT)
were within the range of 1.0e8.0 mg/mL. Among the 160
P. aeruginosa isolates, we found 1 multidrug-resistant isolate (0.6%)
and the isolate was conﬁrmed to produce metallo-b-lactamase.
According to the CLSI breakpoint M100-S20, susceptible and
resistant rates for PIPC were 87.5% and 12.5%, respectively. Pro-
portions of susceptible/intermediate/resistant for carbapenems
were 71.9/11.9/16.3 for IPM and 81.9/4.4/13.8 for MEPM.4. Discussion
The Japanese Society of Chemotherapy (JSC) established a
nationwide surveillance network in 2006 to establish the resource
of information about antimicrobial susceptibility of bacterial
pathogens in Japan. Our research focuses on major seven major
bacterial respiratory pathogens, such as S. aureus, S. pneumoniae,
S. pyogenes, H. inﬂuenzae, M. catarrhalis, K. pneumoniae and
P. aeruginosa. It is desirable that analysis of antimicrobial suscep-
tibility is done with the use of bacterial strains that actually cause
the infections. To analyze the actual pathogens causing infections,
we collected clinical isolates only from well-diagnosed adult pa-
tients with respiratory tract infections (RTIs).
Our surveillance was conducted for four consecutive years from
2006. The total number of strains at surveillance conducted in
2006, 2007, 2008, 2009 and 2010 were 887, 1108, 987, 635 and 955,
respectively. To reﬂect the trend of pathogens of respiratory in-
fections in Japan, we think we should increase the scope of the
survey by reﬂecting results with a greater numbers of pathogens.
The ratio of MRSAwas as high as 50.5% that was decreased from
58.5% in RTI 2009 [2]. These MRSA strains are susceptible to ABK,
VCM, TEIC and LZD except that a few strains somewhat less sus-
ceptible (MIC 8.0 mg/mL) to TEIC. Although the emergence of
resistant MRSA against VCM, TEIC or LZD has already been reported
in Japan, such a resistant strain was not detected in this surveil-
lance. The MRSAwith a MIC of 2.0 mg/mL to VCMwas 5.8% of MRSA.
MRSA isolates with VCM MIC at 2.0 mg/mL are categorized in sus-
ceptible strains, however, the isolates can be associated with
treatment failures, mainly in bloodstream infection [6]. Therefore,
this population should be observed continuously in the next
surveillance.
Since the surveillance in 2009 [2], the susceptibility of
S. pneumoniae to PCG was categorized with the new criteria of
breakpoint MICs, and the proportion of PSSP/PISP/PRSP was found
to be 99:1:0. These ﬁndings were similar to those in RTI 2009
(94:6:0) and suggest that penicillin is still effective against
community-acquired pneumonia caused by S. pneumoniae but
penicillin-intermediate strains are partly present.
Table 6
Antibacterial susceptibility of Haemophilus inﬂuenzae (all strains and b-lactamase-producing strains).
Antimicrobial agent All strains, n ¼ 182 b-lactamase (þ), n ¼ 20
MIC (mg/ml) Susceptibility (%) MIC (mg/ml) Susceptibility (%)
50% 90% Range S I R 50% 90% Range S I R
PCG 4 32 0.125 to 256 e e e 256 256 4 to 256 e e e
ABPC 2 32 0.125 to 256 37.9 17.6 44.5 128 256 4 to 256 0 0 100
SBT/ABPC 2 8 0.06 to 16 59.3 e 40.7 8 8 1 to 8 30.0 e 70.0
CVA/AMPC 4 8 0.06 to 16 78.0 e 22.0 4 8 0.5 to 16 65.0 e 35.0
PIPC 0.06 1 0.06 to 256 e e e 64 256 0.25 to 256 e e e
TAZ/PIPC 0.06 0.125 0.06 to 0.5 100 e 0 0.06 0.125 0.06 to 0.125 100 e 0
CCL 16 64 0.06 to 256 46.7 8.2 45.1 32 64 4 to 128 35.0 10.0 55.0
CFDN 2 8 0.06 to 16 44.5 e 55.5 2 4 0.25 to 8 30.0 e 70.0
CFPN 1 2 0.06 to 8 e e e 1 2 0.06 to 2 e e e
CDTR 0.125 0.25 0.06 to 1 e e e 0.125 0.25 0.06 to 0.5 e e e
CEZ 8 128 0.5 to 256 e e e 32 128 2 to 128 e e e
CMZ 8 32 0.5 to 64 e e e 8 16 2 to 16 e e e
CTM 8 64 0.125 to 128 e e e 16 64 1 to 64 e e e
CAZ 0.25 0.5 0.06 to 4 99.5 e 0.5 0.25 0.5 0.06 to 0.5 100 e 0
CTRX 0.125 0.25 0.06 to 1 100 e 0 0.125 0.25 0.06 to 0.5 100 e 0
CFPM 1 2 0.06 to 4 97.8 e 2.2 1 2 0.125 to 2 100 e 0
CZOP 4 16 0.06 to 32 e e e 8 16 0.125 to 16 e e e
IPM 1 2 0.06 to 8 99.5 e 0.5 1 2 0.25 to 4 100 e 0
PAPM 0.5 2 0.06 to 4 e e e 0.5 1 0.125 to 4 e e e
MEPM 0.125 0.25 0.06 to 1 97.8 e 2.2 0.125 0.25 0.06 to 0.5 100 e 0
BIPM 2 4 0.06 to8 e e e 2 4 0.25 to 4 e e e
DRPM 0.25 1 0.06 to 4 e e e 0.25 1 0.06 to 1 e e e
FRPM 1 2 0.06 to 8 e e e 2 2 0.25 to 4 e e e
AZT 0.5 2 0.06 to 8 96.7 e 3.3 0.5 1 0.06 to 1 100 e 0
GM 1 2 0.25 to 2 e e e 2 2 0.5 to 2 e e e
TOB 2 4 0.25 to 4 e e e 2 4 0.5 to 4 e e e
AMK 4 8 0.5 to 16 e e e 8 8 2 to 8 e e e
ABK 4 4 1 to 8 e e e 4 4 2 to 8 e e e
EM 4 8 0.125 to 16 e e e 4 8 2 to 8 e e e
CAM 4 8 0.125 to 32 91.8 7.1 1.1 4 8 2 to 16 90.0 10.0 0
AZM 1 2 0.06 to 4 100 e 0 1 2 0.5 to 4 100 e 0
CPFX 0.06 0.06 0.06 to 16 99.5 e 0.5 0.06 0.06 0.06 100 e 0
LVFX 0.06 0.06 0.06 to 8 99.5 e 0.5 0.06 0.06 0.06 100 e 0
TFLX 0.06 0.06 0.06 to 32 e e e 0.06 0.06 0.06 e e e
MFLX 0.06 0.06 0.06 to 4 98.9 e 1.1 0.06 0.06 0.06 100 e 0
PZFX 0.06 0.06 0.06 to 8 e e e 0.06 0.06 0.06 e e e
GRNX 0.06 0.06 0.06 to 4 e e e 0.06 0.06 0.06 e e e
STFX 0.06 0.06 0.06 to 0.25 e e e 0.06 0.06 0.06 e e e
MINO 0.25 0.5 0.125 to 2 e e e 0.5 0.5 0.25 to 0.5 e e e
CLDM 8 16 0.5 to 64 e e e 8 16 2 to 16 e e e
The susceptibility of 40 antimicrobial agents against 182 strains of H. inﬂuenzae was determined.
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PCG, we also compared the ratio of the S. pneumoniae isolation in
each year with the previous criteria, which was determined by
reference to the susceptibility breakpoint for meningitis (0.06 mg/
mL). Although the proportion of PSSP/PISP/PRSP of 2006 and 2007
were similar level (61:35:4 and 65:30:5, respectively), the sus-
ceptibility of S. pneumoniae to PCG continuously decreased and the
prevalence in 2010 was 43:42:15. Because it is difﬁcult to detect
these alarming trends by the new criteria of breakpoint MICs,
careful watching using the previous criteria should be continuously
needed.
ConcerningH. inﬂuenzae, half of the strains in the present survey
showed decreased susceptibility to ABPC without production of b-
lactamase; BLNAI (17.6%) and BLNAR (33.5%). The ratio of BLNAI and
BLNAR in adults is thought to be lower than in children [7]. The b-
lactamase-producing clavulanic acid/ampicillin-resistant strains
(BLPACR) have been also increasing and reached 4.8% of clinical
isolates in children [7]. In this surveillance, we observed 7 (3.8%)
BLPACR strains and the prevalence was similar to children, sug-
gesting that BLPACR may be increasing in both children and adults.
BLPACR can be included in the b-lactamase positive population. All
seven ﬂuoroquinolones demonstrated extremely strong activity
(MIC90  0.06 mg/mL) against H. inﬂuenzae strains, regardless oftheir ABPC susceptibility. Among the rest of agents, PIPC, TAZ/PIPC,
CDTR, CTRX, and MEPM showed strong activities (MIC90s of
0.125e1.0 mg/mL) against BLNAS, BLNAI and BLNAR strains. TAZ
markedly restored the activity of PIPC against BLPAR (MIC90
decreased from 256 mg/mL to 1.0 mg/mL).
The susceptibilities of M. catarrhalis in the present survey
showed that b-lactamase inhibitors restored the activities of pen-
icillins against these strains: SBT decreased the MIC90 of ABPC from
16 to 0.25 mg/mL. The data suggest that most of the strains were
resistant to penicillins because of b-lactamase production. For the
treatment of M. catarrhalis infections, carbapenems, macrolides,
and ﬂuoroquinolones may be recommended because these drugs
showed strong activities, with MIC90s of 0.06e0.25 mg/mL.
The prevalence of ESBL strains has become a concern in recent
years. In 1990s, the ratio of ESBL among K. pneumoniae and E. coli
was 0.3% and <0.1%, respectively [8]. The prevalence of this study
(2.9%) was elevated when compared with the RTI 2009 (1.3%). The
increasing tendency was also observed in previous reports [9,10].
The improvement of susceptibilities of b-lactams due to b-lacta-
mase inhibitors might suggest that b-lactamase-producers
including ESBL-producing strains.
In M100-S20 breakpoint criteria for K. pneumoniae [3], no
carbapenem-resistant isolate was observed. However, when based
Table 7
Antibacterial susceptibility of b-lactamase-non-producing Haemophilus inﬂuenzae
Antimicrobial agent BLNAS [ABPC  1, b-lactamase ()], n ¼ 69 BLNAI [ABPC ¼ 2, b-lactamase ()], n ¼ 32 BLNAR [ABPC  4, b-lactamase ()],n ¼ 61
MIC (mg/ml) Susceptibility (%) MIC (mg/ml) Susceptibility (%) MIC (mg/ml) Susceptibility (%)
50% 90% Range S I R 50% 90% Range S I R 50% 90% Range S I R
PCG 0.5 2 0.125 to 8 e e e 4 4 1 to 8 e e e 8 8 2 to 16 e e e
ABPC 0.25 1 0.125 to 1 100 0 0 2 2 2 0 100 0 4 8 4 to 16 0 0 100
SBT/ABPC 0.25 1 0.06 to 2 100 e 0 2 2 2 to 4 96.9 e 3.1 4 8 2 to 16 3.3 e 96.7
CVA/AMPC 0.5 2 0.06 to 4 100 e 0 4 4 2 to 8 90.6 e 9.4 4 8 2 to 16 50.8 e 49.2
PIPC 0.06 0.125 0.06 to 0.125 e e e 0.06 0.125 0.06 to 0.25 e e e 0.125 0.125 0.06 to 0.25 e e e
TAZ/PIPC 0.06 0.06 0.06 to 0.25 100 e 0 0.06 0.125 0.06 to 0.25 100 e 0 0.06 0.125 0.06 to 0.5 100 e 0
CCL 4 16 0.06 to 64 79.7 11.6 8.7 16 64 2 to 128 46.9 15.6 37.5 32 64 4 to 256 13.1 0 86.9
CFDN 0.25 4 0.06 to 8 79.7 e 20.3 2 8 0.5 to 16 46.9 e 53.1 8 8 1 to 16 8.2 e 91.8
CFPN 0.06 1 0.06 to 2 e e e 1 2 0.06 to 4 e e e 2 4 0.5 to 8 e e e
CDTR 0.06 0.25 0.06 to 0.5 e e e 0.125 0.25 0.06 to 0.5 e e e 0.25 0.25 0.125 to 1 e e e
CEZ 2 16 0.5 to 64 e e e 2 64 1 to 256 e e e 32 128 1 to 256 e e e
CMZ 2 8 0.5 to 32 e e e 8 32 2 to 64 e e e 8 64 2 to 64 e e e
CTM 2 32 0.125 to 64 e e e 8 64 1 to 64 e e e 32 64 1 to 128 e e e
CAZ 0.125 0.5 0.06 to 1 100 e 0 0.25 0.5 0.06 to 2 100 e 0 0.25 1 0.06 to 4 98.4 e 1.6
CTRX 0.06 0.25 0.06 to 0.25 100 e 0 0.25 0.25 0.06 to 0.5 100 e 0 0.25 0.5 0.06 to 1 100 e 0
CFPM 0.125 2 0.06 to 2 100 e 0 1 2 0.25 to 4 96.9 e 3.1 2 2 0.5 to 4 95.1 e 4.9
CZOP 0.25 8 0.06 to 8 e e e 8 16 0.5 to 32 e e e 8 16 4 to 32 e e e
IPM 0.5 2 0.06 to 2 100 e 0 1 2 0.125 to 4 100 e 0 1 2 0.25 to 8 98.4 e 1.6
PAPM 0.5 1 0.06 to 2 e e e 0.5 2 0.06 to 2 e e e 1 2 0.125 to 4 e e e
MEPM 0.06 0.125 0.06 to 0.25 100 e 0 0.125 0.25 0.06 to 0.5 100 e 0 0.25 0.5 0.06 to 1 93.4 e 6.6
BIPM 0.5 4 0.06 to 8 e e e 2 4 0.06 to 4 e e e 4 8 0.5 to 8 e e e
DRPM 0.125 0.5 0.06 to 1 e e e 0.5 1 0.06 to 1 e e e 0.5 2 0.06 to 4 e e e
FRPM 0.5 2 0.06 to 2 e e e 2 2 0.5 to 4 e e e 2 4 0.5 to 8 e e e
AZT 0.06 1 0.06 to 8 98.6 e 1.4 0.5 1 0.06 to 4 96.9 e 3.1 1 2 0.25 to 4 93.4 e 6.6
GM 1 2 0.25 to 2 e e e 1 2 0.5 to 2 e e e 1 2 0.5 to 2 e e e
TOB 2 4 0.5 to 4 e e e 2 4 0.5 to 4 e e e 2 4 0.25 to 4 e e e
AMK 4 8 0.5 to 8 e e e 4 8 2 to 8 e e e 4 8 2 to 16 e e e
ABK 4 4 1 to 8 e e e 2 4 2 to 4 e e e 4 4 2 to 8 e e e
EM 2 4 0.125 to 8 e e e 4 4 0.25 to 16 e e e 4 8 1 to16 e e e
CAM 4 8 0.125 to 16 95.7 4.3 0 4 8 0.25 to 32 90.6 6.3 3.1 8 16 2 to 32 88.5 9.9 1.6
AZM 1 2 0.06 to 2 100 e 0 1 2 0.125 to 2 100 e 0 1 2 0.25 to 4 100 e 0
CPFX 0.06 0.06 0.06 to 16 98.6 e 1.4 0.06 0.06 0.06 to 1 100 e 0 0.06 0.06 0.06 to0.125 100 e 0
LVFX 0.06 0.06 0.06 to 8 98.6 e 1.4 0.06 0.06 0.06 to 1 100 e 0 0.06 0.06 0.06 100 e 0
TFLX 0.06 0.06 0.06 to 32 e e e 0.06 0.06 0.06 to 1 e e e 0.06 0.06 0.06 e e e
MFLX 0.06 0.125 0.06 to 4 98.6 e 1.4 0.06 0.06 0.06 to 2 96.9 e 3.1 0.06 0.06 0.06 to 0.125 100 e 0
PZFX 0.06 0.06 0.06 to 8 e e e 0.06 0.06 0.06 to 1 e e e 0.06 0.06 0.06 to 0.25 e e e
GRNX 0.06 0.06 0.06 to 4 e e e 0.06 0.06 0.06 to 2 e e e 0.06 0.06 0.06 to 0.125 e e e
STFX 0.06 0.06 0.06 to 0.25 e e e 0.06 0.06 0.06 e e e 0.06 0.06 0.06 e e e
MINO 0.25 0.5 0.125 to 2 e e e 0.25 0.5 0.125 to 1 e e e 0.5 0.5 0.125 to 1 e e e
CLDM 8 16 0.5 to 32 e e e 4 16 1 to 64 e e e 8 16 2 to 64 e e e
The susceptibility of 40 antimicrobial agents against 162 strains of b-lactamase-non-producing H. inﬂuenzae was determined.
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Table 8
Antibacterial susceptibility of Moraxella catarrhalis.
Antibacterial agent MIC (mg/ml) Susceptibility (%)
50% 90% Range S I R
PCG 16 32 0.06 to 64 e e e
ABPC 4 16 0.06 to 16 e e e
SBT/ABPC 0.125 0.25 0.06 to 0.25 e e e
CVA/AMPC 0.125 0.25 0.06 to 0.5 100 e 0
PIPC 4 8 0.06 to 16 e e e
TAZ/PIPC 0.06 0.06 0.06 e e e
CCL 1 4 0.25 to 32 94.6 4.0 1.4
CFDN 0.25 0.5 0.06 to 1 e e e
CFPN 0.5 1 0.06 to 2 e e e
CDTR 0.5 1 0.06 to 4 e e e
CEZ 8 16 0.5 to 32 e e e
CMZ 0.5 1 0.06 to 1 e e e
CTM 1 2 0.25 to 4 e e e
CAZ 0.125 0.5 0.06 to 0.5 100 e 0
CTRX 1 2 0.06 to 8 97.3 e 2.7
CFPM 1 4 0.125 to 8 e e e
CZOP 2 4 0.25 to 8 e e e
IPM 0.06 0.125 0.06 to 0.25 e e e
PAPM 0.06 0.06 0.06 e e e
MEPM 0.06 0.06 0.06 e e e
BIPM 0.06 0.06 0.06 e e e
DRPM 0.06 0.06 0.06 e e e
FRPM 0.25 0.5 0.06 to 1 e e e
AZT 2 2 0.25 to 4 e e e
GM 0.125 0.125 0.06 to 0.25 e e e
TOB 0.25 0.25 0.06 to 0.5 e e e
AMK 0.5 1 0.25 to 2 e e e
ABK 0.25 0.25 0.06 to 0.5 e e e
EM 0.25 0.5 0.06 to 1 97.3 2.7 0
CAM 0.125 0.25 0.06 to 0.5 100 0 0
AZM 0.06 0.06 0.06 to 0.125 100 0 0
CPFX 0.06 0.06 0.06 to 1 100 e 0
LVFX 0.06 0.125 0.06 to 2 100 e 0
TFLX 0.06 0.06 0.06 to 0.125 e e e
MFLX 0.06 0.125 0.06 to 1 e e e
PZFX 0.06 0.06 0.06 to 1 e e e
GRNX 0.06 0.06 0.06 to 0.25 e e e
STFX 0.06 0.06 0.06 to 0.125 e e e
MINO 0.125 0.125 0.06 to 0.25 e e e
CLDM 4 8 2 to 8 0 20.3 79.7
The susceptibility of 40 antimicrobial agents against 74 strains of M. catarrhalis was
determined.
Table 9
Antibacterial susceptibility of Klebsiella pneumoniae.
Antibacterial agent MIC (mg/ml) Susceptibility (%)
50% 90% Range S I R
ABPC 32 128 4 to 256 3.6 15.8 80.6
SBT/ABPC 4 8 1 to 64 93.5 3.6 2.9
CVA/AMPC 2 4 0.5 to 64 97.1 2.2 0.7
PIPC 4 16 0.25 to 256 90.6 5.1 4.3
TAZ/PIPC 2 4 0.06 to 256 97.8 1.5 0.7
CCL 0.5 1 0.125 to 256 96.4 0 3.6
CFDN 0.06 0.25 0.06 to 128 96.4 0.7 2.9
CFPN 0.25 1 0.06 to 128 e e e
CDTR 0.125 0.5 0.06 to 128 e e e
CEZ 1 2 0.5 to 256 79.1 13 7.9
CMZ 0.5 2 0.125 to 128 99.3 0 0.7
CTM 0.125 0.25 0.06 to 256 e e e
CAZ 0.125 0.25 0.06 to 128 98.6 0 1.4
CTRX 0.06 0.125 0.06 to 256 97.1 0 2.9
CFPM 0.06 0.06 0.06 to 32 98.6 0.7 0.7
CZOP 0.06 0.125 0.06 to 256 e e e
IPM 0.25 0.5 0.06 to 2 100 0 0
PAPM 0.125 0.25 0.06 to 1 e e e
MEPM 0.06 0.06 0.06 to 4 100 0 0
BIPM 0.125 0.5 0.06 to 1 e e e
DRPM 0.06 0.125 0.06 to 2 e e e
FRPM 0.25 0.5 0.06 to 16 e e e
AZT 0.06 0.125 0.06 to 256 97.8 0 2.2
GM 0.25 0.5 0.125 to 1 100 0 0
TOB 0.5 1 0.25 to 4 100 0 0
AMK 1 2 0.125 to 4 100 0 0
ABK 0.5 0.5 0.25 to 2 e e e
AZM 8 16 1 to 128 e e e
CPFX 0.06 0.25 0.06 to 128 95.7 0.7 3.6
LVFX 0.06 0.25 0.06 to 64 96.4 0.7 2.9
TFLX 0.06 0.125 0.06 to 32 e e e
MFLX 0.125 0.5 0.06 to 64 e e e
PZFX 0.06 0.25 0.06 to 32 e e e
GRNX 0.125 0.5 0.06 to 128 e e e
STFX 0.06 0.125 0.06 to 4 e e e
MINO 2 4 0.06 to 128 95.0 3.6 1.4
The susceptibility of 36 antimicrobial agents against 139 strains of K. pneumoniae
was determined.
Table 10
Antibacterial susuceptibility of Pseudomonas aeruginosa.
Anitibacterial agent MIC (mg/ml) Susceptibility (%)
50% 90% Range S I R
PIPC 8 128 0.25 to 256 87.5 e 12.5
TAZ/PIPC 8 128 0.125 to 256 87.5 e 12.5
CAZ 2 32 0.25 to 128 84.4 4.4 11.2
CTRX 64 256 0.5 to 256 15.6 23.1 61.3
CFPM 4 16 0.25 to 256 81.9 13.7 4.4
CZOP 2 16 0.125 to 256 e e e
IPM 2 16 0.06 to 32 71.9 11.9 16.3
PAPM 4 16 0.06 to 64 e e e
MEPM 0.5 16 0.06 to 64 81.9 4.4 13.8
BIPM 0.5 16 0.06 to 64 e e e
DRPM 0.5 8 0.06 to 64 e e e
AZT 8 32 0.06 to 256 65.6 13.2 21.2
GM 2 4 0.06 to 256 95.0 3.8 1.2
TOB 1 2 0.06 to 256 98.1 0 1.9
AMK 4 8 0.25 to 256 98.1 0 1.9
ABK 2 4 0.06 to 256 e e e
CPFX 0.25 8 0.06 to 64 75.6 5.0 19.4
LVFX 1 16 0.06 to 256 67.5 12.5 20.0
TFLX 0.25 32 0.06 to 32 e e e
MFLX 2 16 0.06 to 256 e e e
PZFX 0.5 8 0.06 to 256 e e e
GRNX 2 32 0.06 to 256 e e e
STFX 0.25 4 0.06 to 8 e e e
MINO 16 128 0.5 to 256 e e e
The susceptibility of 35 antimicrobial agents against 160 strains of P. aeruginosawas
determined.
K. Yanagihara et al. / J Infect Chemother 21 (2015) 410e420 419on the updated criteria inM100-S21 [11], one strainwas considered
to be intermediate for imipenem and resistant for meropenem.
In the present survey, only one (0.6%) isolate of the 160
P. aeruginosa isolate was metallo-b-lactamase (MBL)-producing
multidrug-resistant. The proportion of MBL-producing
P. aeruginosa was at a similar level to a previous report in which
MBL-producing P. aeruginosa was detected at 1.6% [10].
CLSI changed the break points of penicillins and carbapenems
against P. aeruginosa in 2012 [12]. We also evaluated the resistant
isolates according to the M100-S22 breakpoint criteria. Among
penicillins, the intermediate range was newly categorized
(32e64 mg/mL) and the susceptible strains for PIPC and TAZ/PIPC
were shifted from 87.5% in M100-S20 to 79.4% and 80.0%, respec-
tively. According to the M100-S22, proportions of susceptible/in-
termediate/resistant among P. aeruginosa were 67.5/4.4/28.1 for
IPM and 76.9/5.0/18.1 for MEPM. Because the change of breakpoint
criteria affects the proportions, the continuous evaluation will be
also required in the next surveillance.
STFX was newly added in the present study. STFX showed stable
activities to all species except for MRSA. However, we should keep
appropriate use of antibiotics to prevent the emergence of resistant
strain.
We think our surveillance data will be a useful reference for the
treatment of respiratory infections in our country. There is
K. Yanagihara et al. / J Infect Chemother 21 (2015) 410e420420substantial evidence that the overuse of antibiotics is a major cause
for the emergence of resistance in respiratory pathogens. To pre-
vent the further spread of antimicrobial resistance in respiratory
pathogens, proper antibiotic use is needed. We should also
continue the surveillance to determine the actual situation of the
resistance shown by bacterial respiratory pathogens to antimicro-
bial agents.
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